VRTX vs MRNA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
VRTX · Vertex Pharmaceuticals$547.09 ▲ 0.85%
MRNA · Moderna$254.19 ▲ 5.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- VRTX +29.9%
- MRNA +926.6%
Head to head
| Metric | VRTX | MRNA |
|---|---|---|
| Price | $547.09 | $254.19 |
| Change today | ▲ 0.85% | ▲ 5.27% |
| Market cap | $138.71B | $101.48B |
| Return, 3 months | +4.4% | +325.0% |
| Return, year to date | +20.7% | +762.0% |
| Return, 1 year | +33.6% | +935.8% |
| P/E (TTM) | 35.2 | – |
| P/B | 6.6 | 15.0 |
| P/E percentile vs own 5y | 97th | 1st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +12.5% | +4.4% |
| Net profit growth (YoY) | +6.5% | +5.2% |
| Gross margin | 86.0% | 22.8% |
| Operating margin | 37.9% | -150.2% |
| Net margin | 35.0% | -142.6% |
| Return on equity | 23.5% | -39.0% |
| Analyst target vs. price | +14.4% | -42.3% |
| Analyst buy share | 95% | 15% |
| RSI (14) | 58 | 64 |
| 30-day volatility | 32.0% | 101.4% |
| Max drawdown, 1 year | -15.2% | -34.2% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VRTX is the largest of the group by market value.
- MRNA has returned the most over the past year.
- VRTX is growing revenue fastest.
- VRTX keeps the most profit per dollar of sales.
- VRTX has been the calmest stock over the last 30 days.